Lantern Pharma Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

LTRN$0.46-22.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 15. Exhibit and Financial Statement Schedules

(a) The following documents are filed as part of this report:

(1)	Financial Statements

Report of Independent Registered Public Accounting Firm (PCAOB ID No. 274)	F-2
Consolidated Balance Sheets – December 31, 2025 and 2024	F-3
Consolidated Statements of Operations for the Years Ended December 31, 2025 and 2024	F-4
Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2025 and 2024	F-5
Consolidated Statements of Stockholders’ Equity (Deficit) for the Years Ended December 31, 2025 and 2024	F-6
Consolidated Statements of Cash Flow for the Years Ended December 31, 2025 and 2024	F-7
Notes to Consolidated Financial Statements	F-8

(2)	Financial Statement Schedules

All financial statement schedules are omitted because the information called for is not required or is shown either in the consolidated financial statements or in the notes thereto.

(3)

Exhibits

The following exhibits are filed herewith or incorporated by reference herein:

Exhibit No.	Description
3.1(a)	Certificate of Conversion (Texas)
3.2(a)	Certificate of Conversion (Delaware)
3.3(a)	Certificate of Incorporation
3.4(b)	Certificate of Amendment to Certificate of Incorporation
3.5(b)	Amended and Restated Certificate of Incorporation
3.1.(vi)(a)	By-laws
4.1(d)	Specimen Stock Certificate evidencing shares of common stock
4.2(k)	Description of Capital Stock
10.1(l)	Second Amended and Restated 2018 Equity Incentive Plan dated October 20, 2022
10.2(m)	Amendment to Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan
10.3+(a)	Employment Agreement dated July 23, 2018 with Panna Sharma
10.4+(f)	Amendment to Employment Agreement dated May 18, 2020 with Panna Sharma
10.5+(c)	Employment Agreement dated May 18, 2020 with David Margrave
10.6(o)	Amendment to Employment Agreement with Kishor Bhatia dated December 28, 2023
10.7(o)	Amendment to Employment Agreement with David Margrave dated December 28, 2023
10.8+(a)	Form of Indemnification Agreement
10.9#(a)	Technology License Agreement dated January 15, 2015, with AF Chemicals, LLC
10.10#(a)	Assignment Agreement dated as of January 5, 2018 with BioNumerik Pharmaceuticals, Inc.
10.11#(a)	Addendum to Technology License Agreement dated February 8, 2016, with AF Chemicals, LLC
10.12+(c)	Employment Agreement dated May 18, 2020 with Kishor G Bhatia
10.13(g)	API Services Project Agreement dated July 10, 2020 with Patheon API Service
10.14#(h)	Second Addendum to Technology License Agreement dated December 30, 2020 with AF Chemicals, LLC
10.15(n)	Additional Amendment to Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan
10.16(p)	Amendment to Employment Agreement with Kishor Bhatia dated January 1, 2025
19.1(p)	Lantern Pharma Inc. Insider Trading Policy
21.1*	List of Subsidiaries

23.1*	Consent of EisnerAmper LLP, independent registered public accounting firm
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
97.1(o)	Lantern Pharma Inc. Executive Officer Clawback Policy
101.INS*	Inline XBRL Instance Document
101.SCH*	Inline XBRL Taxonomy Extension Schema
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase
104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

(a)	Incorporated by reference from the Registration Statement on Form S-1 filed April 16, 2020.
(b)	Incorporated by reference from Current Report on Form 8-K filed June 17, 2020.
(c)	Incorporated by reference from the Registration Statement on Form S-1/A filed May 19, 2020.
(d)	Incorporated by reference from the Registration Statement on Form S-1/A filed May 12, 2020.
(e)	Incorporated by reference from Current Report on Form 8-K filed August 21, 2020.
(f)	Incorporated by reference from the Registration Statement on Form S-1/A filed June 8, 2020.
(g)	Incorporated by reference from Quarterly Report on Form 10-Q for the period ending September 30, 2020.
(h)	Incorporated by reference from the Registration Statement on Form S-1 filed January 8, 2021.
(i)	Incorporated by reference from Exhibit 1.1 of the Registration Statement on Form S-1/A filed May 19, 2020.
(m)	Incorporated by reference from Exhibit A to Registrant’s Definitive Proxy Statement filed April 28, 2023.
(n)	Incorporated by reference from Exhibit A to Registrant’s Definitive Proxy Statement filed April 29, 2024.
+	Indicates a management control or any compensatory plan, contract or arrangement.
#	Certain confidential portions of this Exhibit were omitted by means of marking such portions with an asterisk (the Mark) because the identified confidential portions (i) are not material and (ii) are of the type that the Registrant treats as private and confidential.

*	Filed herewith.

**	Furnished with this report

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.